Meta Analysis Evaluates Hypokalemia Risks Associated with Androgen Receptor Axis Targeted TherapiesNew Analysis Shows Risk of Low Potassium with Prostate Cancer Drugs

This meta-analysis evaluates the safety profile of androgen receptor axis-targeted therapies (ARATs), specifically focusing on the incidence of hypokalemia in patients diagnosed with advanced prostate cancer. By analyzing data from a large cohort of 9,298 patients, the study quantifies the risks associated with abiraterone, enzalutamide, and combination regimens compared to control groups. The findings are critical for clinicians managing electrolyte imbalances in oncology settings.

The primary outcome measured was the incidence of all-grade hypokalemia. The analysis revealed a statistically significant increase in cases among patients receiving ARATs (RR = 3.11; 95% CI: 1.88-5.15, P < 0.001). This overall risk is driven largely by specific components of the treatment regimen, necessitating careful monitoring of potassium levels during therapy.

When examining individual agents, abiraterone showed a significantly elevated risk for all-grade hypokalemia (RR = 3.25; 95% CI: 1.75-6.02). In contrast, enzalutamide alone did not demonstrate a statistically significant difference in potassium levels compared to controls (RR = 1.16; 95% CI: 0.96-1.39). This distinction suggests that the mechanism of action or associated side effects of abiraterone specifically contribute more heavily to electrolyte instability.

Combination therapies involving both abiraterone and enzalutamide showed a markedly higher risk for all-grade hypokalemia (RR = 4.62; 95% CI: 2.65-8.03). The data suggests that combining these agents may compound the physiological stressors leading to potassium depletion, making combination regimens particularly high-risk from a metabolic standpoint.

Regarding severe complications, the incidence of grade $≥$ 3 hypokalemia was significantly higher in patients receiving ARATs (RR = 4.54; 95% CI: 2.42-8.51). This indicates that a substantial portion of the cases identified are clinically significant and may require immediate intervention to prevent cardiac complications or other severe systemic effects.

The most pronounced risk signal was observed in combination regimens regarding severe hypokalemia, with an RR of 9.34 (95% CI: 1.71-50.90). While the confidence interval is wide due to limited data for this specific subgroup, the trend indicates a substantial escalation in severity when multiple ARATs are utilized concurrently.

Clinicians should be aware that abiraterone and combination therapies significantly increase the likelihood of potassium depletion. Proactive management and regular monitoring of serum potassium levels are essential for patients on these regimens to ensure safety and maintain treatment adherence. The findings underscore a clear need for vigilant electrolyte surveillance in advanced prostate cancer management.